Targeting Solid Tumors With BTK Inhibitors

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 May 3

PMID 33937249

Citations 10

Authors

Fatih M Uckun

Taracad Venkatachalam

Affiliations

Soon will be listed here.

Abstract

The repurposing of FDA-approved Bruton's tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients. Here we review the emerging evidence regarding the clinical potential of BTK inhibitors in solid tumor therapy. The use of BTK inhibitors may through lead optimization and translational research lead to the development of new and effective combination regimens for metastatic and/or therapy-refractory solid tumor patients.

Citing Articles

Development of a prognostic gene signature and exploration of P4HA1 in the modulation of cuproptosis in colorectal cancer.

Jiang R, Ruan L, Ding T, Wan H, Chen Y, Zhu X Sci Rep. 2024; 14(1):31766.

PMID: 39738206 PMC: 11686350. DOI: 10.1038/s41598-024-82625-y.

BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia.

Schmidlechner L, Nagel I, Vater I, Cascorbi I, Kaehler M Oncol Lett. 2024; 28(3):424.

PMID: 39021736 PMC: 11253089. DOI: 10.3892/ol.2024.14557.

Influence of Bruton's Tyrosine Kinase (BTK) on Epithelial-Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC).

Leichtle F, Betzler A, Eizenberger C, Lesakova K, Ezic J, Drees R Int J Mol Sci. 2023; 24(17).

PMID: 37685940 PMC: 10487612. DOI: 10.3390/ijms241713133.

Roles of STAT3 in the pathogenesis and treatment of glioblastoma.

Fu W, Hou X, Dong L, Hou W Front Cell Dev Biol. 2023; 11:1098482.

PMID: 36923251 PMC: 10009693. DOI: 10.3389/fcell.2023.1098482.

BTK, the new kid on the (oncology) block?.

Grassilli E, Cerrito M, Lavitrano M Front Oncol. 2022; 12:944538.

PMID: 35992808 PMC: 9386470. DOI: 10.3389/fonc.2022.944538.

References

Chen S, Cai C, Sowalsky A, Ye H, Ma F, Yuan X . BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res. 2018; 78(18):5203-5215. PMC: 6139052. DOI: 10.1158/0008-5472.CAN-17-3615. View

Creagh T, Ruckle J, Tolbert D, Giltner J, Eiznhamer D, Dutta B . Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother. 2001; 45(5):1379-86. PMC: 90477. DOI: 10.1128/AAC.45.5.1379-1386.2001. View

Makowska A, Wolff L, Saczewski F, Bednarski P, Kornicka A . Synthesis and cytotoxic evaluation of benzoxazole/benzothiazole-2-imino-coumarin hybrids and their coumarin analogues as potential anticancer agents. Pharmazie. 2019; 74(11):648-657. DOI: 10.1691/ph.2019.9664. View

Campbell R, Chong G, Hawkes E . Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. J Clin Med. 2018; 7(4). PMC: 5920436. DOI: 10.3390/jcm7040062. View

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S . Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Res. 2016; 76(8):2125-36. PMC: 4873459. DOI: 10.1158/0008-5472.CAN-15-1490. View

Lin M, Wang J, Hsieh Y, Zheng J, Cho E . NO functionalized coumarin derivatives suppress cancer progression and facilitate apoptotic cell death in KRAS mutant colon cancer. Chem Biol Interact. 2019; 309:108708. DOI: 10.1016/j.cbi.2019.06.021. View

Masso-Valles D, Jauset T, Serrano E, Sodir N, Pedersen K, Affara N . Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res. 2015; 75(8):1675-81. PMC: 6773609. DOI: 10.1158/0008-5472.CAN-14-2852. View

Bergin A, Loi S . Triple-negative breast cancer: recent treatment advances. F1000Res. 2019; 8. PMC: 6681627. DOI: 10.12688/f1000research.18888.1. View

Feng Y, Duan W, Cu X, Liang C, Xin M . Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). Expert Opin Ther Pat. 2019; 29(4):217-241. DOI: 10.1080/13543776.2019.1594777. View

10.

Dubovsky J, Beckwith K, Natarajan G, Woyach J, Jaglowski S, Zhong Y . Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013; 122(15):2539-49. PMC: 3795457. DOI: 10.1182/blood-2013-06-507947. View

11.

Wei L, Su Y, Lin C, Chao T, Huang S, Huynh T . Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 2016; 7(43):69961-69975. PMC: 5342527. DOI: 10.18632/oncotarget.11572. View

12.

Flavin M, Rizzo J, Khilevich A, Kucherenko A, SHEINKMAN A, Vilaychack V . Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers. J Med Chem. 1996; 39(6):1303-13. DOI: 10.1021/jm950797i. View

13.

Uckun F, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C . Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg Med Chem. 2006; 15(2):800-14. DOI: 10.1016/j.bmc.2006.10.050. View

14.

Wang X, Wong J, Sevinsky C, Kokabee L, Khan F, Sun Y . Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Mol Cancer Ther. 2016; 15(9):2198-208. PMC: 5145257. DOI: 10.1158/1535-7163.MCT-15-0813. View

15.

Sagiv-Barfi I, Kohrt H, Czerwinski D, Ng P, Chang B, Levy R . Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015; 112(9):E966-72. PMC: 4352777. DOI: 10.1073/pnas.1500712112. View

16.

Zhang L, Xu Z . Coumarin-containing hybrids and their anticancer activities. Eur J Med Chem. 2019; 181:111587. DOI: 10.1016/j.ejmech.2019.111587. View

17.

Giordano F, Vaira V, Cortinovis D, Bonomo S, Goedmakers J, Brena F . p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. J Exp Clin Cancer Res. 2019; 38(1):260. PMC: 6570906. DOI: 10.1186/s13046-019-1199-7. View

18.

Overman M, Javle M, Davis R, Vats P, Kumar-Sinha C, Xiao L . Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020; 8(1). PMC: 7057435. DOI: 10.1136/jitc-2020-000587. View

19.

Zhang T, Harrison M, ODonnell P, Alva A, Hahn N, Appleman L . A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020; 126(20):4485-4497. PMC: 7590121. DOI: 10.1002/cncr.33067. View

20.

Kim H . Development of BTK inhibitors for the treatment of B-cell malignancies. Arch Pharm Res. 2019; 42(2):171-181. DOI: 10.1007/s12272-019-01124-1. View